This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.89% per year. These returns cover a period from January 1, 1988 through March 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
by Zacks Equity Research
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
BDXPositive Net Change ALGNNegative Net Change CAHPositive Net Change HSICNegative Net Change
earnings medical medical-devices
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CORT's first-quarter 2025 earnings call, investors are likely to focus on the sales performance of its Cushing's syndrome drug, Korlym.
CORTNegative Net Change BPMCPositive Net Change CTMXPositive Net Change ARGXPositive Net Change
medical
Earnings Season: 3 Companies Raising Guidance
by Derek Lewis
Raising guidance? In this uncertainty? These three companies say yes.
BSXPositive Net Change CLSNegative Net Change CNCPositive Net Change
earnings medical tech-stocks
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
by Zacks Equity Research
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
NVSPositive Net Change LLYPositive Net Change BAYRYNegative Net Change INCYPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Best Growth Stocks to Buy for April 29th
by Zacks Equity Research
UHS, NFG and MPTI made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 29, 2025
UHSPositive Net Change NFGNegative Net Change MPTINegative Net Change
construction medical oil-energy
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXPositive Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Universal Health Q1 Earnings Beat on Strong Acute Care Admissions
by Zacks Equity Research
UHS continues to witness growth in acute care facilities' patient days, while behavioral health care services witness decline.
UHSPositive Net Change ANIPPositive Net Change AVAHNo Net Change ONCPositive Net Change
earnings finance medical
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
by Zacks Equity Research
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
NVSPositive Net Change RHHBYPositive Net Change PFEPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What to Expect From These 3 MedTech Stocks This Earnings Season?
by Zacks Equity Research
Here is a sneak peek into how these three MedTech stocks, ALGN, TNDM and ICLR, may fare in their quarterly results, slated to be released tomorrow.
ALGNNegative Net Change ICLRPositive Net Change TNDMPositive Net Change
earnings medical
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
by Zacks Equity Research
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
SNYPositive Net Change AZNPositive Net Change MRKPositive Net Change AMGNPositive Net Change
biotechs earnings medical pharmaceuticals vaccines
ISRG vs. SYK: Which Robotic-Device Innovator Is a Better Buy?
by Indrajit Bandyopadhyay
Both are leaders in robotic-assisted surgery ??? Intuitive Surgical in soft tissue procedures and Stryker in orthopedic surgeries. Which company is a better bet now?
SYKPositive Net Change ISRGPositive Net Change
medical medical-devices
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
APositive Net Change DXCMPositive Net Change EDAPPositive Net Change GMEDNegative Net Change
medical medical-devices
Labcorp Q1 Earnings Surpass Estimates, Revenues Miss, Stock Gains
by Zacks Equity Research
LH delivers better-than-expected earnings in the first quarter of 2025.
BSXPositive Net Change LHPositive Net Change ANGONegative Net Change ITGRNegative Net Change
earnings medical medical-devices
3 Unconventional Cannabis Stocks to Watch in 2025
by Sundeep Ganoria
Think cannabis investing is all hype? These three unconventional stocks could change your mind - and your portfolio - in 2025.
PMPositive Net Change JAZZPositive Net Change CRBPPositive Net Change
biotechs marijuana medical pharmaceuticals pot-stocks
New Strong Buy Stocks for April 29th
by Zacks Equity Research
MATX, SNN, ALEX, PCB and LTH have been added to the Zacks Rank #1 (Strong Buy) List on April 29, 2025.
SNNPositive Net Change ALEXPositive Net Change MATXPositive Net Change PCBNegative Net Change LTHNegative Net Change
consumer-discretionary finance medical reit transportation
Company News for Apr 29, 2025
by Zacks Equity Research
Companies In The News Are: DPZ, RVTY, OPRA, INMD.
DPZNegative Net Change OPRAPositive Net Change INMDNegative Net Change RVTYNegative Net Change
internet-content medical retail
Zacks Industry Outlook Highlights HCA Healthcare, Tenet Healthcare, Universal Health Services and Community Health Systems
by Zacks Equity Research
HCA Healthcare, Tenet Healthcare, Universal Health Services and Community Health Systems have been highlighted in this Industry Outlook article.
UHSPositive Net Change THCPositive Net Change CYHPositive Net Change HCAPositive Net Change
medical
EMEA Growth & Product Launches to Support Boston Scientific Stock
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
BSXPositive Net Change MASINegative Net Change PBHNegative Net Change HIMSNegative Net Change
medical medical-devices
Will BAX's Q1 Earnings Improve Following Transformation Completion?
by Zacks Equity Research
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
BAXPositive Net Change APositive Net Change EDAPPositive Net Change GMEDNegative Net Change
medical medical-devices
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
by Zacks Equity Research
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
MASINegative Net Change FMSPositive Net Change GKOSPositive Net Change RVTYNegative Net Change
earnings medical medical-devices
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
by Zacks Equity Research
HUM's first-quarter results are likely to benefit from higher Medicare stand-alone PDP revenues.
HUMPositive Net Change CORPositive Net Change ADUSPositive Net Change ACRVNegative Net Change
earnings finance insurance medical
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
by Zacks Equity Research
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
BDXPositive Net Change CAHPositive Net Change HSICNegative Net Change MMSINegative Net Change
earnings medical medical-devices
Are Options Traders Betting on a Big Move in Agilent Technologies Stock?
by Zacks Equity Research
Investors need to pay close attention to A stock based on the movements in the options market lately.
APositive Net Change
medical
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
by Zacks Equity Research
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
MASINegative Net Change FMSPositive Net Change GKOSPositive Net Change AVTRPositive Net Change
earnings medical medical-devices
Should You Buy, Sell, or Hold GE Healthcare Before Q1 Earnings?
by Zacks Equity Research
GEHC Q1 results are likely to reflect strong growth in Imaging, Ultrasound, and AI, fueled by robust procedure volumes and global partnerships despite China headwinds.
CORPositive Net Change ANIPPositive Net Change HIMSNegative Net Change GEHCPositive Net Change
medical medical-devices